SAA1 deficiency alleviates cardiac remodeling by inhibiting NF-κB/p38/JNK and TGFβ/Smad pathways

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Inflammation Research

Background:

• Heart failure (HF) involves cardiac remodeling, a process driven by inflammation.
• Serum amyloid A1 (SAA1) is an inflammation regulator with largely unknown cardiac functions.
• Understanding SAA1's role is crucial for developing novel HF therapies.

Purpose of the Study:

• To investigate the role of Serum amyloid A1 (SAA1) in pressure overload-induced cardiac remodeling.
• To assess the impact of SAA1 deficiency on cardiac hypertrophy and fibrosis.
• To elucidate SAA1's specific contribution to the pathophysiology of heart failure.

Main Methods:

• Utilized a mouse model of cardiac remodeling via transverse aortic banding (TAB).
• Compared SAA1-deficient (SAA1-/-) mice with wild-type littermates.
• Assessed cardiac function, cardiomyocyte size, and fibrotic markers post-TAB surgery.

Main Results:

• SAA1 expression increased in the TAB-induced pressure overload model.
• SAA1-/- mice exhibited significantly reduced cardiac fibrosis after 8 weeks of TAB compared to wild-type mice.
• No significant differences in cardiomyocyte hypertrophy were observed between SAA1-/- and wild-type mice post-TAB.
• Sham-operated groups showed no significant differences in cardiac fibrosis, indicating TAB-specific effects.

Conclusions:

• SAA1 deficiency attenuates cardiac fibrosis in response to pressure overload.
• SAA1 plays a significant role in the development of cardiac fibrosis during heart remodeling.
• Targeting SAA1 may represent a potential therapeutic strategy for mitigating cardiac fibrosis in heart failure.